Buy & Sell Spirit Airlines Incorporated (SAVE) – Spirit Airlines Incorporated Price Today
Key Stats
- $118.28MMarket Cap
- IndustrialsSector
- -3M Drawdown
- $6.70BEnterprise Value
- -Dividend Yield
- 47 daysTypical Hold Time
Spirit Airlines Incorporated (SAVE) is currently valued at a market capitalization of $118.28M, with an enterprise value of $6.70B. Over the past 52 weeks, Spirit Airlines Incorporated has traded between a low of $1.08 and a high of $3.4, highlighting its annual price range. On average, investors hold Spirit Airlines Incorporated for approximately 47 days, indicating typical investor behavior on the platform.
About Spirit Airlines Incorporated
Spirit Airlines Inc serves the United States, Latin America, and Caribbean as an airline operator. It primarily offers customers unbundled base fares to strip out any unneeded travel amenities. If needed, a customer can elect for additional options at an extra charge. Flight crews are entirely interchangeable across all aircraft, and maintenance and other support services are simplified due to not having an overly complex fleet. The company has one operating segment, air transportation, owing to its system wide route structure. It may decide to expand its network if a market is underserved or overpriced. The majority of revenue is derived from the United States.
Most Recent News
American Airlines suspends six domestic routes this summer amid rising fuel costs linked to Iran conflict
American Airlines will temporarily suspend six domestic routes from August to September due to rising jet fuel costs driven by the Iran conflict. The affected routes include flights from Los Angeles to Cleveland, Columbus, Pittsburgh, and Washington ...

OpenAI plans major upgrade to boost ChatGPT amid IPO and competition with Anthropic.
OpenAI is preparing its biggest upgrade yet, transforming ChatGPT into a superapp with multiple tools like coding and AI agents to better compete with Anthropic. This move aims to attract more corporate clients and increase revenue as OpenAI readies ...

Repatha cuts first major cardiovascular event risk by 29% in high-risk diabetes patients, new trial data show
New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients wi...
